Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA okays Thoratec's implantable VAD (ventricular assist device) trial:

This article was originally published in Clinica

Executive Summary

Thoratec has gained a conditional approval from the US FDA to begin a clinical trial of an implantable version of its FDA-approved paracorporeal ventricular assist device (VAD). The product, which has an outer housing made of titanium alloy, weighs under a pound (less than 0.5kg). It will be assessed in 30 patients at 10 heart centres, says the Pleasanton, California company. Thoratec is one of three companies in recent weeks to gain US approval to start clinical trials of an implantable VAD or heart replacement device (see Clinica No 946, p 19).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel